<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xml:lang="en" article-type="research-article" xmlns:xlink="http://www.w3.org/1999/xlink">
<?release-delay 0|0?>
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">OL</journal-id>
<journal-title-group>
<journal-title>Oncology Letters</journal-title></journal-title-group>
<issn pub-type="ppub">1792-1074</issn>
<issn pub-type="epub">1792-1082</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name></publisher></journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3892/ol.2013.1370</article-id>
<article-id pub-id-type="publisher-id">ol-06-02-0556</article-id>
<article-categories>
<subj-group>
<subject>Articles</subject></subj-group></article-categories>
<title-group>
<article-title>Small compound 6-<italic>O</italic>-angeloylplenolin induces caspase-dependent apoptosis in human multiple myeloma cells</article-title></title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>LIU</surname><given-names>YING</given-names></name><xref rid="af1-ol-06-02-0556" ref-type="aff"><sup>1</sup></xref><xref rid="fn1-ol-06-02-0556" ref-type="fn"><sup>&#x0002A;</sup></xref><xref rid="c1-ol-06-02-0556" ref-type="corresp"/></contrib>
<contrib contrib-type="author">
<name><surname>DONG</surname><given-names>YING</given-names></name><xref rid="af2-ol-06-02-0556" ref-type="aff"><sup>2</sup></xref><xref rid="fn1-ol-06-02-0556" ref-type="fn"><sup>&#x0002A;</sup></xref></contrib>
<contrib contrib-type="author">
<name><surname>ZHANG</surname><given-names>BO</given-names></name><xref rid="af3-ol-06-02-0556" ref-type="aff"><sup>3</sup></xref></contrib>
<contrib contrib-type="author">
<name><surname>CHENG</surname><given-names>YONG-XIAN</given-names></name><xref rid="af4-ol-06-02-0556" ref-type="aff"><sup>4</sup></xref><xref ref-type="corresp" rid="c2-ol-06-02-0556"/></contrib></contrib-group>
<aff id="af1-ol-06-02-0556">
<label>1</label>The Shenzhen Key Lab of Gene and Antibody Therapy, Center for Biotech and BioMedicine and Division of Life Sciences, Shenzhen Graduate School, Tsinghua University, Shenzhen, Guangdong 518055, 
<country>P.R. China</country></aff>
<aff id="af2-ol-06-02-0556">
<label>2</label>Department of Oncology, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310009, 
<country>P.R. China</country></aff>
<aff id="af3-ol-06-02-0556">
<label>3</label>National Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, 
<country>P.R. China</country></aff>
<aff id="af4-ol-06-02-0556">
<label>4</label>State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, Yunnan 650204, 
<country>P.R. China</country></aff>
<author-notes>
<corresp id="c1-ol-06-02-0556">Correspondence to: Dr Ying Liu, The Shenzhen Key Lab of Gene and Antibody Therapy, Center for Biotech and BioMedicine and Division of Life Sciences, Graduate School at Shenzhen, Tsinghua University, Shenzhen, Guangdong 518055, P.R. China, E-mail: <email>liu.ying2012@sz.tsinghua.edu.cn</email></corresp>
<corresp id="c2-ol-06-02-0556">Dr Yong-Xian Cheng, State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, 132 Lanhei Road, Kunming, Yunnan 650204, P.R. China, Email: <email>yxcheng@mail.kib.ac.cn</email></corresp><fn id="fn1-ol-06-02-0556" fn-type="equal">
<label>&#x0002A;</label>
<p>Contributed equally</p></fn></author-notes>
<pub-date pub-type="ppub">
<month>08</month>
<year>2013</year></pub-date>
<pub-date pub-type="epub">
<day>30</day>
<month>05</month>
<year>2013</year></pub-date>
<volume>6</volume>
<issue>2</issue>
<fpage>556</fpage>
<lpage>558</lpage>
<history>
<date date-type="received">
<day>03</day>
<month>01</month>
<year>2013</year></date>
<date date-type="accepted">
<day>17</day>
<month>05</month>
<year>2013</year></date></history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2013, Spandidos Publications</copyright-statement>
<copyright-year>2013</copyright-year>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0">
<license-p>This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.</license-p></license></permissions>
<abstract>
<p>6-<italic>O</italic>-angeloylplenolin (6-OAP) is a sesquiterpene lactone agent that has been previously demonstrated to inhibit the growth of multiple myeloma (MM) cells through mitotic arrest with accumulated cyclin B1. In the present study, the levels of apoptosis were analyzed in dexamethasone-sensitive (MM.1S), dexamethasone-resistant (U266) and chemotherapy-sensitive (RPMI 8226) myeloma cell lines. Enhanced apoptosis was identified following a 48-h incubation with 6-OAP (0&#x02013;10 <italic>&#x003BC;</italic>M) that induced a dose-dependent decrease in pro-casp-3 and the cleavage of its substrate, anti-poly (ADP-ribose) polymerase (PARP). In addition, time-dependent cleavage of PARP was also detected in U266 and MM.1S cells. The mechanism of 6-OAP cytotoxicity in all cell lines was associated with the induction of apoptosis with the presence of cleaved caspase-3 and PARP. In conclusion, 6-OAP-induced apoptosis is caspase-dependent. These observations are likely to provide a framework for future studies of 6-OAP therapy in MM.</p></abstract>
<kwd-group>
<kwd>6-<italic>O</italic>-angeloylplenolin</kwd>
<kwd>multiple myeloma</kwd>
<kwd>apoptosis</kwd>
<kwd>caspase</kwd></kwd-group></article-meta></front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Multiple myeloma (MM) or plasma cell myeloma is a malignant disorder characterized by the accumulation of differentiated B cells (plasma cells). The incompletely differentiated plasma cells are characterized by deregulated apoptosis (<xref rid="b1-ol-06-02-0556" ref-type="bibr">1</xref>). The treatment of MM remains unsatisfactory and new agents that specifically target key signaling pathways required for myeloma growth or survival are urgently required.</p>
<p>6-<italic>O</italic>-angeloylplenolin (6-OAP; <xref rid="f1-ol-06-02-0556" ref-type="fig">Fig 1A</xref>) is a sesquiterpene lactone isolated from <italic>Centipeda minima</italic> that has been studied in hematological and solid forms of cancer and has been revealed to exhibit activity without significant toxicity (<xref rid="b2-ol-06-02-0556" ref-type="bibr">2</xref>&#x02013;<xref rid="b4-ol-06-02-0556" ref-type="bibr">4</xref>). The results of our preliminary study demonstrated that 6-OAP inhibits the proliferation of human MM cells by inducing the arrest of mitosis and inhibiting specific key pathways (<xref rid="b5-ol-06-02-0556" ref-type="bibr">5</xref>). However, whether 6-OAP-induced mitosis arrest and pathway inhibition are followed by apoptosis requires further study. Therefore, the aim of the present study was to investigate the apoptotic effect of 6-OAP against human myeloma cells.</p></sec>
<sec sec-type="methods">
<title>Materials and methods</title>
<sec>
<title>Reagents</title>
<p>6-OAP with a purity &#x02264;99.5&#x00025; was extracted from <italic>Centipeda minima</italic> (L.) as described previously (<xref rid="b4-ol-06-02-0556" ref-type="bibr">4</xref>). The 6-OAP was then dissolved in DMSO (Sigma-Aldrich, St. Louis, MO, USA) to produce a stock solution of 10<sup>&#x02212;2</sup> M, which was stored at &#x02212;20&#x000B0;C.</p></sec>
<sec>
<title>Cell culture</title>
<p>MM.1S, U266 and RPMI 8226 human MM cell lines were purchased from the American Type Culture Collection (Manassas, VA, USA). The cells were cultured in RPMI-1640 medium supplemented with 10&#x00025; (for U266) or 15&#x00025; (for RPMI 8226 and MM.1S) fetal bovine serum (Hyclone Laboratories, Inc., Logan, UT, USA) and incubated in a humidified atmosphere with 5&#x00025; CO<sub>2</sub> at 37&#x000B0;C.</p></sec>
<sec>
<title>Patient samples</title>
<p>CD138<sup>&#x0002B;</sup> cells from a single patient with MM were isolated with informed consent from bone marrow (BM) mononuclear cells using positive immunomagnetic column separation (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany). The purity of the CD138<sup>&#x0002B;</sup> cells was &#x0003E;97&#x00025; as determined by flow cytometry. This study was approved by the ethics committee of Shenzhen Graduate School, Tsinghua University, Shenzhen, China.</p></sec>
<sec>
<title>DNA fragmentation</title>
<p>The MM cells were collected and lysed in 0.5 ml lysis buffer containing 10 mM Tris (pH 8.0), 10 mM EDTA and 0.05&#x00025; Triton X-100. The lysate was centrifuged, RNase (0.2 mg/ml) was added and the lysate was incubated for 30 min at 37&#x000B0;C. Proteinase K (0.1 mg/ml) and sodium dodecyl sulfate (SDS; final concentration 1&#x00025;) were added, followed by incubation at 50&#x000B0;C for 16 h. DNA was extracted with phenol/chloroform and then chloroform, prior to being precipitated with ethanol and sodium acetate and electrophoresed on 1.5&#x00025; agarose gels, and then visualized with ethidium bromide (EB) staining.</p></sec>
<sec>
<title>Flow cytometric assays for Annexin-V (AV)</title>
<p>Cell apoptosis was evaluated by AV detection using an AV-FITC kit (BD Biosciences, Franklin Lakes, NJ, USA), according to the manufacturer&#x02019;s instructions.</p></sec>
<sec>
<title>Western blot</title>
<p>Cell pellets were lysed in RIPA buffer containing 50 mM Tris (pH 8.0), 150 mM NaCl, 0.1&#x00025; SDS, 0.5&#x00025; deoxycholate, 1&#x00025; NP-40, 1 mM DTT, 1 mM NaF, 1 mM sodium vanadate and a protease inhibitor cocktail (Sigma-Aldrich). Protein extracts were quantitated, loaded on 8&#x02013;12&#x00025; SDS-polyacrylamide gels, electrophoresed and then transferred to a nitrocellulose membrane (Whatman plc, Maidstone, Kent). The membrane was incubated with primary antibody, washed and incubated with horseradish peroxidase-conjugated secondary antibody. Detection was performed using a chemiluminescent western detection kit (Cell Signaling Technology, Inc., Danvers, MA, USA). The antibodies used were anti-caspase-3, anti-poly (ADP-ribose) polymerase (PARP; Cell Signaling Technology, Inc.) and anti-&#x003B2;-actin (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA).</p></sec>
<sec>
<title>Statistical analysis</title>
<p>All experiments were repeated at least three times and the data are presented as the mean &#x000B1; SD unless noted otherwise. P&#x0003C;0.05 was considered to indicate a statistically significant difference.</p></sec></sec>
<sec sec-type="results">
<title>Results</title>
<sec>
<title>6-OAP induces apoptosis in MM cells</title>
<p>The levels of apoptosis were analyzed using the DNA fragmentation assay in dexamethasone-sensitive (MM.1S) and dexamethasone-resistant (U266) myeloma cell lines treated with 6-OAP. As demonstrated in <xref rid="f1-ol-06-02-0556" ref-type="fig">Fig. 1B</xref>, marked DNA ladders were observed in MM.1S and U266 cells treated with 6-OAP, indicative of apoptosis detection.</p>
<p>In addition, AV staining was conducted to assess apoptosis in U266 and chemotherapy-sensitive RPMI 8226 cell lines treated with 6-OAP. Using flow cytometry, 7.5 <italic>&#x003BC;</italic>M 6-OAP was identified to induce apoptosis at a ratio of 28 and 46&#x00025; in U266 and RPMI 8226 cells, respectively (<xref rid="f2-ol-06-02-0556" ref-type="fig">Fig. 2</xref>). These results indicate that 6-OAP induces apoptosis in MM cells.</p></sec>
<sec>
<title>6-OAP-induced apoptosis in MM cells is caspase-dependent</title>
<p>The apoptotic pathways that ultimately lead to the activation of effector caspases (casp-3, -2 and -7) and the cleavage of PARP have been characterized in MM (<xref rid="b6-ol-06-02-0556" ref-type="bibr">6</xref>). Therefore, a western blot analysis was used to detect the activation of the casp-3 effector caspase and its substrate, PARP, in the MM cells. 6-OAP was demonstrated to induce a significant dose-dependent decrease in pro-casp-3 and the cleavage of its substrate, PARP, in the three cell lines, indicating the activation of casp-3 (<xref rid="f3-ol-06-02-0556" ref-type="fig">Fig. 3A</xref>). 6-OAP also markedly induced the cleavage of PARP in a time-dependent manner in the U266 and MM.1S cells (<xref rid="f3-ol-06-02-0556" ref-type="fig">Fig. 3B</xref>). In addition, the expression of pro-casp-3 and the cleavage of PARP was investigated in CD138<sup>&#x0002B;</sup> primary cells isolated from a single MM patient (<xref rid="f3-ol-06-02-0556" ref-type="fig">Fig. 3C</xref>). The results of the western blot analysis demonstrated that 6-OAP significantly induces the activation of casp-3. These observations indicate that 6-OAP induces caspase-dependent apoptosis in MM cells.</p></sec></sec>
<sec sec-type="discussion">
<title>Discussion</title>
<p>The natural agent, 6-OAP, was initially demonstrated to exhibit anti-bacterial and anti-protozoal activities (<xref rid="b7-ol-06-02-0556" ref-type="bibr">7</xref>&#x02013;<xref rid="b9-ol-06-02-0556" ref-type="bibr">9</xref>). However, more recently, studies have demonstrated an anti-tumor activity for 6-OAP in solid tumors and hematological malignancies (<xref rid="b2-ol-06-02-0556" ref-type="bibr">2</xref>&#x02013;<xref rid="b4-ol-06-02-0556" ref-type="bibr">4</xref>). Our previous observations found that 6-OAP induces the arrest of mitosis in MM cells by the activation of the spindle assembly checkpoint and the accumulation of cyclin B1. In addition, 6-OAP was identified to inhibit the Jak2/Stat3 and Akt signaling pathways, thereby blocking the facilitation of the BM microenvironment on the MM cells. 6-OAP has also been found to induce marked inhibition of NF-&#x003BA;B in MM cells (<xref rid="b5-ol-06-02-0556" ref-type="bibr">5</xref>). However, to date, no studies have determined whether the inhibitory effects of 6-OAP on the cell cycle and certain signal pathways ultimately result in apoptosis. Therefore, in the present study, the effect of 6-OAP on apoptosis in MM cells was analyzed.</p>
<p>Apoptosis is an active process that ultimately leads to the activation of endonucleases and the cleavage of DNA into fragments of 180&#x02013;200 bp. The extrinsic and intrinsic apoptotic pathways that ultimately lead to activation of effector caspases (casp-3, -2 and -7) have also been characterized (<xref rid="b10-ol-06-02-0556" ref-type="bibr">10</xref>,<xref rid="b11-ol-06-02-0556" ref-type="bibr">11</xref>). The present study demonstrated that 6-OAP-treated MM cells exhibited evident DNA fragments of 180&#x02013;200 bp (<xref rid="f1-ol-06-02-0556" ref-type="fig">Fig. 1B</xref>), indicating that 6-OAP induces apoptosis in MM cells. The activation of the effector caspases was also analyzed and 6-OAP was found to induce casp-3 activation, followed by PARP cleavage in various MM cell lines (<xref rid="f3-ol-06-02-0556" ref-type="fig">Fig. 3</xref>), indicating that 6-OAP induces caspase-dependent apoptosis in MM cells. In conclusion, 6-OAP induces growth inhibition in human MM cells using a number of different mechanisms, including the arrest of mitosis and the inhibition of certain signaling pathways. These different mechanisms ultimately lead to caspase-dependent apoptotic cell death.</p></sec></body>
<back>
<ack>
<p>This study was supported, in part, by the National Natural Science Foundation of China (No. 81101835) and the Foundation of Zhejiang Provincial Education Department (No. Y200804683).</p></ack>
<ref-list>
<title>References</title>
<ref id="b1-ol-06-02-0556"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chauhan</surname><given-names>D</given-names></name><name><surname>Anderson</surname><given-names>KC</given-names></name></person-group><article-title>Apoptosis in multiple myeloma: therapeutic implications</article-title><source>Apoptosis</source><volume>6</volume><fpage>47</fpage><lpage>55</lpage><year>2001</year></element-citation></ref>
<ref id="b2-ol-06-02-0556"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Changlong</surname><given-names>L</given-names></name><name><surname>Hezhen</surname><given-names>W</given-names></name><name><surname>Yongping</surname><given-names>H</given-names></name><name><surname>Yanfang</surname><given-names>Y</given-names></name><name><surname>Yanwen</surname><given-names>L</given-names></name><name><surname>Jianwen</surname><given-names>L</given-names></name></person-group><article-title>6-O-Angeloylenolin induces apoptosis through a mitochondrial/caspase and NF-kappaB pathway in human leukemia HL60 cells</article-title><source>Biomed Pharmacother</source><volume>62</volume><fpage>401</fpage><lpage>409</lpage><year>2008</year></element-citation></ref>
<ref id="b3-ol-06-02-0556"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>M</given-names></name><name><surname>Chung</surname><given-names>HY</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name></person-group><article-title>6-O-Angeloylenolin induced cell-cycle arrest and apoptosis in human nasopharyngeal cancer cells</article-title><source>Chem Biol Interact</source><volume>189</volume><fpage>167</fpage><lpage>176</lpage><year>2011</year></element-citation></ref>
<ref id="b4-ol-06-02-0556"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>LF</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Liang</surname><given-names>HX</given-names></name><name><surname>Liu</surname><given-names>DP</given-names></name><name><surname>Zhou</surname><given-names>GB</given-names></name><name><surname>Cheng</surname><given-names>YX</given-names></name></person-group><article-title>Two new terpene glucosides and antitumor agents from <italic>Centipeda minima</italic></article-title><source>J Asian Nat Prod Res</source><volume>11</volume><fpage>732</fpage><lpage>736</lpage><year>2009</year></element-citation></ref>
<ref id="b5-ol-06-02-0556"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>XQ</given-names></name><name><surname>Liang</surname><given-names>HX</given-names></name><name><surname>Zhang</surname><given-names>FX</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Jin</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>YL</given-names></name><name><surname>Cheng</surname><given-names>YX</given-names></name><name><surname>Zhou</surname><given-names>GB</given-names></name></person-group><article-title>Small compound 6-o-angeloylplenolin induces mitotic arrest and exhibits therapeutic potentials in multiple myeloma</article-title><source>PLoS One</source><volume>6</volume><fpage>e21930</fpage><year>2011</year></element-citation></ref>
<ref id="b6-ol-06-02-0556"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hideshima</surname><given-names>T</given-names></name><name><surname>Richardson</surname><given-names>P</given-names></name><name><surname>Chauhan</surname><given-names>D</given-names></name><name><surname>Palombella</surname><given-names>VJ</given-names></name><name><surname>Elliott</surname><given-names>PJ</given-names></name><name><surname>Adams</surname><given-names>J</given-names></name><name><surname>Anderson</surname><given-names>KC</given-names></name></person-group><article-title>The proteasome inhibitor PS-341 inhibits growth, induces apoptosis and overcomes drug resistance in human multiple myeloma cells</article-title><source>Cancer Res</source><volume>61</volume><fpage>3071</fpage><lpage>3076</lpage><year>2001</year></element-citation></ref>
<ref id="b7-ol-06-02-0556"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>RS</given-names></name><name><surname>Towers</surname><given-names>GH</given-names></name></person-group><article-title>Antibacterial constituents of the Nepalese medicinal herb, <italic>Centipeda minima</italic></article-title><source>Phytochemistry</source><volume>47</volume><fpage>631</fpage><lpage>634</lpage><year>1998</year></element-citation></ref>
<ref id="b8-ol-06-02-0556"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Francois</surname><given-names>G</given-names></name><name><surname>Passreiter</surname><given-names>CM</given-names></name><name><surname>Woerdenbag</surname><given-names>HJ</given-names></name><name><surname>Van</surname><given-names>LM</given-names></name></person-group><article-title>Antiplasmodial activities and cytotoxic effects of aqueous extracts and sesquiterpene lactones from <italic>Neurolaena lobata</italic></article-title><source>Planta Med</source><volume>62</volume><fpage>126</fpage><lpage>129</lpage><year>1996</year></element-citation></ref>
<ref id="b9-ol-06-02-0556"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwikkard</surname><given-names>S</given-names></name><name><surname>van Heerden</surname><given-names>FR</given-names></name></person-group><article-title>Antimalarial activity of plant metabolites</article-title><source>Nat Prod Rep</source><volume>19</volume><fpage>675</fpage><lpage>692</lpage><year>2002</year></element-citation></ref>
<ref id="b10-ol-06-02-0556"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicholson</surname><given-names>DW</given-names></name></person-group><article-title>Caspase structure, proteolytic substrates and function during apoptotic cell death</article-title><source>Cell Death Differ</source><volume>6</volume><fpage>1028</fpage><lpage>1042</lpage><year>1999</year></element-citation></ref>
<ref id="b11-ol-06-02-0556"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnstone</surname><given-names>RW</given-names></name><name><surname>Ruefli</surname><given-names>AA</given-names></name><name><surname>Lowe</surname><given-names>SW</given-names></name></person-group><article-title>Apoptosis: a link between cancer genetics and chemotherapy</article-title><source>Cell</source><volume>108</volume><fpage>153</fpage><lpage>164</lpage><year>2002</year></element-citation></ref></ref-list>
<sec sec-type="display-objects">
<title>Figures</title>
<fig id="f1-ol-06-02-0556" position="float">
<label>Figure 1.</label>
<caption>
<p>6-OAP induces apoptosis in multiple myeloma (MM) cells, as detected by DNA fragmentation assay. (A) Chemical structure of 6-OAP. (B) U266 and MM.1S cells were treated with 6-OAP at the indicated concentrations for 48 h and DNA fragmentation was analyzed. 6-OAP, 6-<italic>O</italic>-angeloylplenolin.</p></caption>
<graphic xlink:href="OL-06-02-0556-g00.tif"/></fig>
<fig id="f2-ol-06-02-0556" position="float">
<label>Figure 2.</label>
<caption>
<p>6-OAP induces apoptosis in multiple myeloma (MM) cells detected by Annexin V staining. U266 and RPMI 8226 cells were treated with 6-OAP for 24 h. Annexin V staining was determined by flow cytometry. 6-OAP, 6-<italic>O</italic>-angeloylplenolin.</p></caption>
<graphic xlink:href="OL-06-02-0556-g01.tif"/></fig>
<fig id="f3-ol-06-02-0556" position="float">
<label>Figure 3.</label>
<caption>
<p>6-OAP induces caspase-dependent apoptosis of multiple myeloma (MM) cells. (A) U266, MM.1S and RPMI 8226 cells were treated with 6-OAP for 48 h and lyzed, then extracts were subjected to western blot analysis. (B) U266 cells (upper) or MM.1S cells (lower) were treated with 6-OAP for the indicated time points. (C) CD138<sup>&#x0002B;</sup> primary cells isolated from 1 MM patient were treated with or without 6-OAP for 24 h. Total cell lysates were subjected to western blot analysis using antibodies against casp-3, PARP and &#x003B2;-actin. 6-OAP, 6-<italic>O</italic>-angeloylplenolin; casp-3, caspase-3; PARP, anti-poly (ADP-ribose) polymerase.</p></caption>
<graphic xlink:href="OL-06-02-0556-g02.tif"/></fig></sec></back></article>
